SII launches pneumococcal vaccine, PNEUMOSIL indiagazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiagazette.com Daily Mail and Mail on Sunday newspapers.
Serum Institute launches Indiaâs first indigenous pneumococcal vaccine
Serum Institute launches Indiaâs first indigenous pneumococcal vaccine
28 December 2020 | News PNEUMOSIL® comes with the advantage of presence of stereotypes 6A & 19A
The Serum Institute of India has announced the launch of India’s first indigenously developed pneumococcal vaccine – PNEUMOSIL® in the presence of Dr Harsh Vardhan, Minister, Health and Family Welfare.
It has been developed through a collaboration spanning over a decade among Serum Institute of India Pvt Ltd, PATH and Bill and Melinda Gates foundation.
Driven by the philanthropic commitment of SII to protect every family with affordable vaccines, PNEUMOSIL® comes with the advantage of presence of stereotypes 6A & 19A. The composition of the WHO pre-qualified vaccine is specially tailored as per the prevalence of the Top 10 serotypes of S. pneumoniae in India and other regions of the
Share this article
Share this article
PUNE, India and EMERYVILLE, Calif., Dec. 23, 2020 /PRNewswire/ Further strengthening its fight against COVID-19, Serum Institute of India (SIIPL), the world s largest vaccine manufacturer by volume, has partnered with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing and commercializing novel vaccines, and today jointly announced that the first participants have been dosed in the Phase 1 part of the Phase 1/2 clinical trial evaluating SIIPL s vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19.
The Phase 1/2 clinical trial will evaluate the safety and immunogenicity of SIIPL s vaccine candidate consisting of the SARS-COV-2 virus receptor binding domain (RBD) delivered as a virus-like particle (VPL), along with Dynavax s advanced adjuvant CpG 1018 plus alum. The Phase 1 portion of the clinical trial will enroll 39 healthy volunteers and post the completion of the study a decision
Trade Setup For Wednesday: Top 15 Things To Know Before Opening Bell moneycontrol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneycontrol.com Daily Mail and Mail on Sunday newspapers.
1361
New Delhi, December 11
The World Health Organization, national regulatory authorities and vaccine manufacturers in WHO South-East Asia Region discussed fast tracking of COVID-19 vaccine rollout in member countries, a statement said. The vaccine manufacturing and regulatory sectors have a critical role to play in equitable and efficient deployment of vaccines, said Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region, at the two-day virtual meeting that ended on Friday.
The meeting deliberated processes and timelines to fast-track registration of COVID-19 vaccines in countries using the Emergency Use Listing procedures while comprehending the landscape of COVID-19 vaccine production in the region.